Biopharmaceutical News and Research

RSS

Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

20 Feb 2025

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

From MaxCyte, Inc. 13 Feb 2025

Study examines how diet impacts gene expression in fat tissue

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC.

8 Feb 2025

SAB BIO announces positive topline Phase 1 clinical results with potentially disease-modifying T1D therapy SAB-142

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced positive topline data from a Phase 1 trial of SAB-142 in a single-ascending dose among healthy volunteers.

From SAb Biotherapeutics, Inc. 6 Feb 2025

Gyros Protein Technologies introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to support biotherapeutic development

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents.

6 Feb 2025

BEND lipids revolutionize mRNA delivery and gene-editing

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking system and its counterpart on the station.

28 Jan 2025

Research reveals inaccuracies in common gene therapy measurement technique

In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several measurement techniques commonly used in gene therapy.

13 Jan 2025

Menarini Group signs licensing deal with Insilico for promising cancer treatment

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and commercialize a preclinical small molecule targeting high unmet needs in oncology.

10 Jan 2025

World’s largest proteomics study launched by UK Biobank

UK Biobank has today announced the launch of the world's most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments.

9 Jan 2025

New CryoSCAPE technology aims to improve blood sample stability for research

Your blood is a delicate mixture. Researchers and clinicians often use blood to learn what's going on inside our bodies, in part because siphoning off a tube of blood is easier and less painful than taking biopsies of an internal organ.

6 Jan 2025

New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

From Aptamer Group 23 Dec 2024

bit.bio raises $30 million led by M&G Investments

bit.bio, the global leader in cell programming technology, today announced the successful closing of a $30 million financing round led by M&G Investments, a leading international savings and investment company.

18 Dec 2024

Harnessing exosomes to deliver therapeutic proteins

Researchers at The Ottawa Hospital and the University of Ottawa have discovered an 18-digit code that allows proteins to attach themselves to exosomes - tiny pinched-off pieces of cells that travel around the body and deliver biochemical signals.

11 Dec 2024

New study links specific E. coli strains to higher cancer incidence rates

Higher rates of certain cancers in countries, such as the UK, may be linked to two particular strains of bacteria.

6 Dec 2024

Women with genetic risk for depression more likely to develop heart disease

Women who have a high genetic risk of depression are more likely to develop heart disease, University of Queensland researchers have found.

4 Dec 2024

evitria partners with Sapio Sciences to streamline antibody workflow management and reporting

Sapio Sciences, the science-aware™ lab informatics platform, today announced that evitria, a leader in antibody expression services, has selected Sapio’s Electronic Lab Notebook (ELN) and Sapio Report Builder to enhance its sample tracking, data capture, and reporting capabilities.

4 Dec 2024

evitria Partners with Sapio Sciences to Streamline Antibody Workflow Management and Reporting

evitria optimizes antibody expression services, enhancing data capture and reporting capabilities for scientific workflows with Sapio's ELN and Report Builder,

From Sapio Sciences 4 Dec 2024

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies

From Asimov 25 Nov 2024

Enterprise Therapeutics publishes on medicinal chemistry of ETD001, a novel inhaled ENaC blocker for treatment of cystic fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The European Journal of Medicinal Chemistry.

From Enterprise Therapeutics Ltd 25 Nov 2024

New initiative aims to explore diet’s role in lupus care

Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance (LRA), today announced a pioneering funding mechanism to address one of the most common questions about lupus clinical care and management.

22 Nov 2024